In This Article
- Cancer risk is nearly seven-fold in patients with a heart event such as myocardial infarction or heart failure
- In an interview, Emily Lau, MD, cardiology fellow, explained how frontline diagnosis of comorbid patients can be improved to understand cancer risk
Recent study findings show that cancer risk is nearly seven-fold in patients with a heart event such as myocardial infarction or heart failure. While this is useful in understanding cancer risks, there is still no consensus on the mechanism of the association.
In an interview with MD Magazine, Emily Lau, MD, fellow in the Division of Cardiology at the Corrigan Minehan Heart Center of Massachusetts General Hospital, said that anti-inflammatory therapy has lead to a reduction in cardiovascular events in some studies. In a study of the monoclonal antibody canakinumab, investigators found that rates of cardiovascular events and lung cancer were both decreased.
Dr. Lau and colleagues studied a cohort of patients from the Framingham Heart Study, looking into how inflammation-targeting therapies may benefit comorbid patients and how frontline diagnosis of heart events can be improved to reduce cancer risk. She said that their study suggested that patients with high atherosclerotic cardiovascular disease risk should not only be talking to their cardiologist and primary care physician but also to their oncologist about their risk.
While the link between heart events and cancer risk is still unclear, Dr. Lau believes that the field is moving towards research on the connection.
Learn more about the Corrigan Minehan Heart Center
Refer a patient to the Corrigan Minehan Heart Center